An omission to the funding section of the original article was made in error. The following sentence has been added: “Open access funding was provided by the University of Lausanne”.
The original version of this article has been updated.
. 2023 Mar 14;14:1178295. doi: 10.3389/fimmu.2023.1178295
Erratum: CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity
Frontiers Production Office1,*
1
Frontiers Media SA, Lausanne, Switzerland
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
✉
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
Received 2023 Mar 2; Accepted 2023 Mar 2; Collection date 2023.
Keywords: cancer immunotherapy, vaccine peptide, melan-A/MART-1, NY-ESO-1, peptide-HLA binding affinity, TCR-peptide-MHC affinity, human CD8 T cells
Copyright © 2023 Frontiers Production Office
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
PMCID: PMC10043813 PMID: 36999010
This corrects the article "CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity" in volume 13, 973986.